References
- Rakićević L, Kovač M, Radojković D, Radojković M. The ‘VKORC1‘ and ‘CYP2C9‘ gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients: Consideration of hypersensitivity and resistance. Srpski arhiv za celokupno lekarstvo. 2022;150(3-4):156-62. doi: 10.2298/SARH211118013R
- Roco A, Nieto E, Suarez M, et al. A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. Front Pharmacol. 2020;11:325.
- Tong HY, Borobia AM, Quintana-Diaz M, et al. Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial. J Clin Med. 2021;10(13).
- Cullell N, Carrera C, Muino E, et al. Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain. Sci Rep. 2020;10(1):2806.
- Ragia G, Kolovou V, Kolovou G, et al. A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. Pharmacogenomics. 2017;18(1):23-34.
- Gonzalez-Covarrubias V, Urena-Carrion J, Villegas-Torres B, et al. Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol. Front Pharmacol. 2017;8:863.
- Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006;21(1):73-7.
- Schalekamp T, de Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Des. 2010;16(2):187-203.
- Kovac MK, Rakicevic LB, Radojkovic DP. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes. J Thromb Thrombolysis. 2011;32(3):368-71.
- Sun B, Ma S, Xiao F, et al. Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation enjcacy in clinical practice. BMC Cardiovasc Disord. 2023;23(1):279.
- Rathore SS, Agarwal SK, Pande S, et al. Pharmacogenetic aspects of coumarinic oral anticoagulant therapies. Indian J Clin Biochem. 2011;26(3):222-9.
- Krishna Kumar D, Madhan S, Balachander J, et al. Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thromb Res. 2013;131(4):363-7.
- Cerezo-Manchado JJ, Rosafalco M, Anton AI, et al. Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thromb Haemost. 2013;109(1):146-53.
- Borobia AM, Lubomirov R, Ramirez E, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One. 2012;7(7):e41360.
- Bazan NS, Sabry NA, Rizk A, et al. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. Int J Clin Pharm. 2012;34(6):837-44.
- Buzoianu AD, Militaru FC, Vesa SC, et al. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood Cells Mol Dis. 2013;50(3):166-70.
- Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-93.
- Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost. 2007;5(11):2227-34.
- Verde Z, Ruiz JR, Santiago C, et al. A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One. 2010;5(6):e11210.
- Velizarova M, Abedinov P, Svinarov D, et al. Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy. Clin Lab. 2022;68(12).
- Jakjovski K, Labachevski N, Petlichkovski A, et al. Distribution of CYP2C9 and VKORC1 Gene Polymorphisms in Healthy Macedonian Male Population. Macedonian J Med Sciences. 2014;6(4):5.
- Giraldo-Ocampo S, Diaz-Ordonez L, Silva-Cuero YK, et al. Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia. Medicine (Baltimore). 2023;102(30):e34204.
- Zhou Y, Nevosadova L, Eliasson E, Lauschke VM. Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. Hum Genomics. 2023;17(1):15.